Novavax (NVAX) Competitors $7.41 -0.04 (-0.54%) Closing price 06/9/2025 04:00 PM EasternExtended Trading$7.43 +0.02 (+0.27%) As of 06/9/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NVAX vs. BCRX, LGND, FOLD, CLDX, MNKD, INVA, DVAX, OPK, GERN, and RGLSShould you be buying Novavax stock or one of its competitors? The main competitors of Novavax include BioCryst Pharmaceuticals (BCRX), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), MannKind (MNKD), Innoviva (INVA), Dynavax Technologies (DVAX), OPKO Health (OPK), Geron (GERN), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry. Novavax vs. BioCryst Pharmaceuticals Ligand Pharmaceuticals Amicus Therapeutics Celldex Therapeutics MannKind Innoviva Dynavax Technologies OPKO Health Geron Regulus Therapeutics Novavax (NASDAQ:NVAX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation, dividends and community ranking. Which has more volatility & risk, NVAX or BCRX? Novavax has a beta of 2.8, indicating that its stock price is 180% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500. Do insiders & institutionals believe in NVAX or BCRX? 53.0% of Novavax shares are held by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are held by institutional investors. 1.0% of Novavax shares are held by company insiders. Comparatively, 4.8% of BioCryst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts prefer NVAX or BCRX? Novavax presently has a consensus price target of $19.00, indicating a potential upside of 156.58%. BioCryst Pharmaceuticals has a consensus price target of $16.56, indicating a potential upside of 49.49%. Given Novavax's higher possible upside, equities analysts clearly believe Novavax is more favorable than BioCryst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novavax 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Is NVAX or BCRX more profitable? BioCryst Pharmaceuticals has a net margin of -30.01% compared to Novavax's net margin of -32.18%. Company Net Margins Return on Equity Return on Assets Novavax-32.18% N/A -17.05% BioCryst Pharmaceuticals -30.01%N/A -24.06% Does the media refer more to NVAX or BCRX? In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Novavax. MarketBeat recorded 5 mentions for BioCryst Pharmaceuticals and 3 mentions for Novavax. Novavax's average media sentiment score of 1.18 beat BioCryst Pharmaceuticals' score of 0.91 indicating that Novavax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, NVAX or BCRX? BioCryst Pharmaceuticals has lower revenue, but higher earnings than Novavax. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovavax$1.21B0.99-$545.06M$2.652.79BioCryst Pharmaceuticals$503.49M4.60-$226.54M-$0.26-42.60 Does the MarketBeat Community believe in NVAX or BCRX? Novavax received 353 more outperform votes than BioCryst Pharmaceuticals when rated by MarketBeat users. Likewise, 74.02% of users gave Novavax an outperform vote while only 67.16% of users gave BioCryst Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNovavaxOutperform Votes85274.02% Underperform Votes29925.98% BioCryst PharmaceuticalsOutperform Votes49967.16% Underperform Votes24432.84% SummaryNovavax beats BioCryst Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Novavax News Delivered to You Automatically Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVAX vs. The Competition Export to ExcelMetricNovavaxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.20B$3.12B$5.53B$8.64BDividend YieldN/A1.59%5.27%4.18%P/E Ratio-3.2833.3427.3020.19Price / Sales0.99479.02411.18158.87Price / CashN/A168.6838.2534.64Price / Book-1.233.486.984.72Net Income-$545.06M-$72.35M$3.23B$248.00M7 Day Performance4.74%11.25%6.18%4.62%1 Month Performance23.62%22.34%13.60%10.07%1 Year Performance-59.25%-15.53%32.09%14.97% Novavax Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVAXNovavax3.8019 of 5 stars$7.41-0.5%$19.00+156.4%-59.2%$1.20B$1.21B-3.281,990Positive NewsBCRXBioCryst Pharmaceuticals4.3281 of 5 stars$10.71-0.3%$16.56+54.5%+76.1%$2.24B$503.49M-17.58530LGNDLigand Pharmaceuticals4.8102 of 5 stars$102.09-0.1%$146.14+43.2%+34.6%$1.97B$181.49M40.6880Positive NewsFOLDAmicus Therapeutics3.7815 of 5 stars$6.13+1.0%$16.22+164.5%-40.0%$1.89B$543.14M-34.04480Positive NewsAnalyst RevisionCLDXCelldex Therapeutics1.9636 of 5 stars$19.84+0.3%$53.90+171.7%-41.3%$1.32B$7.56M-7.73150Positive NewsMNKDMannKind2.6985 of 5 stars$4.28+3.0%$10.00+133.9%-6.4%$1.30B$297.60M61.07400News CoverageINVAInnoviva4.3726 of 5 stars$20.23+3.3%$55.00+171.9%+33.7%$1.27B$369.84M29.31100Positive NewsDVAXDynavax Technologies4.4476 of 5 stars$9.84+0.5%$24.00+144.0%-14.8%$1.18B$294.62M54.64350News CoveragePositive NewsOPKOPKO Health4.5743 of 5 stars$1.41+3.4%$2.75+95.6%+7.0%$1.12B$689.41M-7.404,200GERNGeron3.2534 of 5 stars$1.41-7.6%$5.06+260.3%-64.7%$894.87M$116.29M-4.3970RGLSRegulus Therapeutics2.2616 of 5 stars$7.94+0.1%$8.50+7.1%+272.2%$549.37MN/A-7.4230Positive News Related Companies and Tools Related Companies BioCryst Pharmaceuticals Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives Celldex Therapeutics Alternatives MannKind Alternatives Innoviva Alternatives Dynavax Technologies Alternatives OPKO Health Alternatives Geron Alternatives Regulus Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVAX) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Imagine you're driving down I-45 between Dallas and Houston. You come up behind an 18-wheeler, flick your s...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWall Street Legend: Crash coming in March—details hereBad News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history give...Chaikin Analytics | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredTrump’s treachery A few months ago, I released a list of six companies I believed were going to appreciate under Trump’s second ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novavax With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
